# Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome

> **NCT03162094** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Avizorex Pharma, S.L.** · enrollment: 172 (estimated)

## Conditions studied

- Dry Eye Syndrome

## Interventions

- **DRUG:** AVX012 Ophthalmic Solution Low dose
- **DRUG:** AVX012 Ophthalmic Solution High dose
- **DRUG:** Placebo (vehicle)

## Key facts

- **NCT ID:** NCT03162094
- **Lead sponsor:** Avizorex Pharma, S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-03
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2018-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03162094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03162094, "Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03162094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*